Antibody specialist Xencor has appointed Mark Lotz as vice president of regulatory affairs and Wayne Saville as vice president of clinical oncology. 13 May 2015
Australia’s CSL Limited today announced that Gordon Naylor will lead the company’s new global influenza vaccine business, which is planned for launch at the start of 2016. 23 April 2015
Dutch privately-held life sciences company Cristal Therapeutics has appointed Jeroen Tonnar as new chief business officer responsible for business development, partnering and licensing activities. 21 April 2015
Danish CNS specialist Lundbeck has entered into an exclusive worldwide license agreement with privately-held US biotech start-up Ovid Therapeutics for gaboxadol. 19 April 2015
Germany’s Merck KGaA has appointed Udit Batra to head the combined life science business following the pending acquisition of US life science company Sigma-Aldrich. 14 April 2015
Takeda Pharmaceuticals USA, the US subsidiary of Japan’s largest drugmaker Takeda, has appointed Ramona Sequeira as president of the US business unit. 13 April 2015
EMD Serono, the US biopharma subsidiary of Germany’s Merck KGaA has appointed Frederick Munschauer as vice president of medical affairs, neurology and immunology. 2 April 2015
UK-based stem cell therapy company ReNeuron is making changes to its board and senior management as it prepares for the next phase of development. 2 April 2015
Konstantinos (Kostas) Kosmatopoulos, a founder of anti-tumor immunotherapy specialist Vaxon Biotech, has become chief executive of the company. 30 March 2015
US biotech Paragon Therapeutics yesterday revealed that biotech industry veteran Susanna High has been appointed as chief executive (CEO). In this newly-created role, Ms High will lead the team’s continued efforts to propel the development of a pipeline of transformative therapies and accelerate their potential impact. 22 November 2024
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
New York-based Mind Medicine, a company developing MM120, a form of LSD (lysergide d-tartrate), for mental health conditions, has announced the appointment of Gregg Pratt, as chief regulatory and quality assurance officer. 19 November 2024
Belgian biotech start-up ExeVir Bio says it has appointed Michael Garrett as its new chief executive (CEO), effective 1 December 2024. 18 November 2024
ALX Oncology Holdings, a Californian immuno-oncology company, has announced the appointment of Alan Sandler as chief medical officer (CMO). 14 November 2024
US ophthalmology specialist Ocular Therapeutix announced that Namrata Saroj has joined the Company on a full-time basis as chief business officer (CBO). Dr Saroj previously served as development strategy consultant to Ocular since February 2024. 14 November 2024
VarmX, a Dutch biotech developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has appointed industry veteran John Glasspool (pictured, above) as chief executive. 12 November 2024
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024
Fennec Pharmaceuticals has announced the addition of three new executives to bolster its leadership team as the company prepares for expanded commercial operations. 28 October 2024